Drug or treatment

Furmonertinib clinical trials

• 15Clinical trials
• 1Country

Newest trials

All recruiting trials (15)

• Vebreltinib plus furmonertinib in EGFR-mutated NSCLC with high PD-L1

  This study tests whether combining vebreltinib with furmonertinib can help people with advanced NSCLC that has EGFR mutations and very high PD-L1 expression.

  Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University · Nanchang, Jianxi · NCT07655622

• Sacituzumab tirumotecan plus furmonertinib for advanced EGFR‑mutant non‑squamous lung cancer after EGFR‑TKI and platinum chemotherapy

  This Phase II trial will test whether combining sacituzumab tirumotecan with furmonertinib helps people with advanced EGFR‑mutant non‑squamous NSCLC who progressed after EGFR‑TKI and platinum chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07548060

• Pulsatile high-dose furmonertinib for EGFR-mutant NSCLC with leptomeningeal metastasis

  This tests whether taking high-dose furmonertinib every other day helps people with EGFR-mutant non-small cell lung cancer that has spread to the leptomeninges.

  Recruiting Guangzhou University of Traditional Chinese Medicine · Guangzhou, Guangdong · NCT07348965

• Furmonertinib plus intrathecal chemotherapy and stereotactic radiotherapy for EGFR‑mutated NSCLC with brain parenchymal and leptomeningeal metastases

  This trial tries to see if taking furmonertinib with spinal‑fluid chemotherapy injections and focused brain radiotherapy helps people with EGFR‑mutated lung cancer who have both brain and leptomeningeal metastases.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Cangzhou, Hebei and 2 other locations · NCT07304739

• Vebreltinib plus furmonertinib for EGFR‑TKI–resistant NSCLC with c‑MET amplification

  This study tests whether giving vebreltinib together with furmonertinib can help people with advanced NSCLC that developed c‑MET amplification after their EGFR‑targeted therapy stopped working.

  Recruiting at 2 sites Phase 1/2 Peking University Cancer Hospital & Institute · Neimeng, Neimeng and 11 other locations · NCT07087223

• Evaluating furmonertinib with chemotherapy versus osimertinib for lung cancer with brain metastases

  This study is testing whether a new drug called furmonertinib combined with chemotherapy works better than osimertinib alone for people with lung cancer that has spread to the brain.

  Recruiting Phase 3 Allist Pharmaceuticals, Inc. · Guangdong, Guangzhou · NCT06970639

• RC108 plus Furmonertinib as first-line treatment for EGFR-mutated, MET-positive advanced NSCLC

  This trial tests whether adding RC108 to Furmonertinib works better than Furmonertinib alone for adults with EGFR-mutated, MET-positive unresectable locally advanced or metastatic non-small cell lung cancer.

  Recruiting at 34 sites Phase 2 RemeGen Co., Ltd. · Beijing and 33 other locations · NCT06962865

• Combining Furmonertinib and Anlotinib for Advanced Lung Cancer with Brain Metastasis

  This study is testing if combining two drugs, Furmonertinib and Anlotinib, can help people with advanced lung cancer that has spread to the brain feel better and live longer.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou · NCT06945705

• Furmonertinib for advanced lung cancer with specific EGFR mutations

  This study is testing a new treatment called furmonertinib to see if it helps people with advanced lung cancer who have certain genetic mutations feel better and live longer.

  Recruiting Phase 3 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06674343

• High-dose furmonertinib alone or with chemotherapy for EGFR-mutant advanced non-small-cell lung cancer after progression on a third-generation EGFR-TKI

  This trial tests whether higher-dose furmonertinib, either by itself or combined with chemotherapy, helps people with EGFR-mutant advanced non-small cell lung cancer that progressed after a third-generation EGFR-TKI.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06652048

• Assessing furmonertinib for lung cancer patients with specific mutations after surgery

  This study is testing if a new drug called furmonertinib can help lung cancer patients with specific mutations stay cancer-free after their surgery.

  Recruiting Phase 2 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06192849

• Furmonertinib before surgery for stage II–IIIB EGFR-mutant NSCLC

  This study tests whether giving furmonertinib before surgery can help shrink tumors in adults with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT05987826

• Treatment for advanced lung cancer using furmonertinib and bevacizumab

  This study is testing a new combination of medications to see if it can help shrink tumors in patients with advanced lung cancer before surgery, making it easier to remove the cancer completely.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT05503667

• Furmonertinib treatment for advanced lung cancer with uncleared ctDNA

  This study is testing if a new lung cancer drug called furmonertinib works better alone or with other treatments for patients whose cancer has certain markers in their blood.

  Recruiting Phase 2 Sun Yat-sen University · Changchun and 25 other locations · NCT05334277

• Assessing Furmonertinib for Non-small Cell Lung Cancer After Surgery

  This study is testing if a new drug called Furmonertinib can help people with stage II-IIIA non-small cell lung cancer feel better after their surgery compared to a placebo.

  Recruiting Phase 3 Allist Pharmaceuticals, Inc. · Suzhou, Jiangsu · NCT04853342

Quick answers

How many clinical trials of Furmonertinib are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 9, Phase 3: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →